Diabetes-related biomarkers and methods of use thereof
First Claim
Patent Images
1. A method of evaluating risk for developing a diabetic condition, the method comprising:
- obtaining biomarker measurement data, wherein the biomarker measurement data is representative of measurements of biomarkers in at least one biological sample from an individual; and
evaluating risk for developing a diabetic condition based on an output from a model, wherein the model is executed based on an input of the biomarker measurement data;
wherein said biomarkers comprise;
(i) at least three biomarkers, where three of the biomarkers are selected from the RDMARKER sets listed in FIG. 6A;
or(ii) at least four biomarkers selected from RDMARKERS;
or(iii) at least three biomarkers, where two biomarkers are selected from ADIPOQ;
CRP;
GLUCOSE;
GPT;
HBA1C;
HSPA1B;
IGFBP1;
IGFBP2;
INS;
LEP; and
TRIG; and
one biomarker is selected from the ALLDBRISKS, CPs, and TLRFs of Table 1, Table 2, and Table 3;
or(iv) at least three biomarkers, where at least one biomarker is selected from GLUCOSE and HBA1C;
at least one biomarker is selected from ADIPOQ, CRP, GPT, HSPA1B, IGFBP1, IGFBP2, INS, LEP, and TRIG; and
at least one biomarker is selected from the ALLDBRISKS, CPs, and TLRFs of Table 1, Table 2, and Table 3;
or(v) at least three biomarkers, where at least two biomarkers are selected from the biomarkers within the group consisting of Core Biomarkers I and Core Biomarkers II and at least a third biomarker is selected from any of the biomarkers listed in Table 4.
6 Assignments
0 Petitions
Accused Products
Abstract
The invention describes biomarkers which can be used to predict the likelihood that an individual will develop Diabetes. The biomarkers can also be used to screen large groups in order to identify individuals at risk of developing Diabetes.
-
Citations
30 Claims
-
1. A method of evaluating risk for developing a diabetic condition, the method comprising:
-
obtaining biomarker measurement data, wherein the biomarker measurement data is representative of measurements of biomarkers in at least one biological sample from an individual; and evaluating risk for developing a diabetic condition based on an output from a model, wherein the model is executed based on an input of the biomarker measurement data; wherein said biomarkers comprise; (i) at least three biomarkers, where three of the biomarkers are selected from the RDMARKER sets listed in FIG. 6A ;
or(ii) at least four biomarkers selected from RDMARKERS;
or(iii) at least three biomarkers, where two biomarkers are selected from ADIPOQ;
CRP;
GLUCOSE;
GPT;
HBA1C;
HSPA1B;
IGFBP1;
IGFBP2;
INS;
LEP; and
TRIG; and
one biomarker is selected from the ALLDBRISKS, CPs, and TLRFs of Table 1, Table 2, and Table 3;
or(iv) at least three biomarkers, where at least one biomarker is selected from GLUCOSE and HBA1C;
at least one biomarker is selected from ADIPOQ, CRP, GPT, HSPA1B, IGFBP1, IGFBP2, INS, LEP, and TRIG; and
at least one biomarker is selected from the ALLDBRISKS, CPs, and TLRFs of Table 1, Table 2, and Table 3;
or(v) at least three biomarkers, where at least two biomarkers are selected from the biomarkers within the group consisting of Core Biomarkers I and Core Biomarkers II and at least a third biomarker is selected from any of the biomarkers listed in Table 4. - View Dependent Claims (3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
-
-
2. A method of evaluating the risk of developing a diabetic condition in a subject by comprising:
-
measuring one or more of Clinical Parameters and Traditional Laboratory Risk Factors; obtaining biomarker measurement data that is representative of measurements of at least two biomarkers in a sample from the subject, wherein the at least two biomarkers are selected from the group consisting of Core Biomarkers I and Core Biomarkers II; and evaluating the risk of developing a diabetic condition in the subject based on an output from a model, wherein the model is executed based on an input of the biomarker measurement data.
-
-
15. A computer readable medium having computer executable instructions for evaluating risk for developing a diabetic condition, the computer readable medium comprising:
-
a routine, stored on the computer readable medium and adapted to be executed by a processor, to store biomarker measurement data representing; (i) at least three biomarkers, where three of the biomarkers are selected from the RDMARKER sets listed in FIG. 6A ;
or(ii) at least four biomarkers selected from RDMARKERS;
or(iii) at least three biomarkers, where two biomarkers are selected from ADIPOQ;
CRP;
GLUCOSE;
GPT;
HBA1C;
HSPA1B;
IGFBP1;
IGFBP2;
INS;
LEP; and
TRIG; and
one biomarker is selected from the ALLDBRISKS, CPs, and TLRFs of Table 1, Table 2, and Table 3;
or(iv) at least three biomarkers, where at least one biomarker is selected from GLUCOSE and HBA1C;
at least one biomarker is selected from ADIPOQ, CRP, GPT, HSPA1B, IGFBP1, IGFBP2, INS, LEP, and TRIG; and
at least one biomarker is selected from the ALLDBRISKS, CPs, and TLRFs of Table 1, Table 2, and Table 3;
or(v) at least three biomarkers, where at least two biomarkers are selected from the biomarkers within the group consisting of Core Biomarkers I and Core Biomarkers II and at least a third biomarker is selected from any of the biomarkers listed in Table 4; and a routine stored on the computer readable medium and adapted to be executed by a processor to analyze the biomarker measurement data to evaluate a risk for developing a diabetic condition.
-
-
16. A diagnostic test system comprising:
-
means for obtaining test results data representing levels of multiple biomarkers in at least one biological sample; means for collecting and tracking test results data for one or more individual biological samples; means for computing an index value from biomarker measurement data according to a DRS Formula, wherein said biomarker measurement data is representative of measured levels of biomarkers, and further wherein said measured levels of biomarkers comprise the levels of; (i) at least three biomarkers, where three of the biomarkers are selected from the RDMARKER sets listed in FIG. 6A ;
or(ii) at least four biomarkers selected from RDMARKERS;
or(iii) at least three biomarkers, where two biomarkers are selected from ADIPOQ;
CRP;
GLUCOSE;
GPT;
HBA1C;
HSPA1B;
IGFBP1;
IGFBP2;
INS;
LEP; and
TRIG; and
one biomarker is selected from the ALLDBRISKS, CPs, and TLRFs of Table 1, Table 2, and Table 3;
or(iv) at least three biomarkers, where at least one biomarker is selected from GLUCOSE and HBA1C;
at least one biomarker is selected from ADIPOQ, CRP, GPT, HSPA1B, IGFBP1, IGFBP2, INS, LEP, and TRIG; and
at least one biomarker is selected from the ALLDBRISKS, CPs, and TLRFs of Table 1, Table 2, and Table 3;
or(v) at least three biomarkers, where at least two biomarkers are selected from the biomarkers within the group consisting of Core Biomarkers I and Core Biomarkers II and at least a third biomarker is selected from any of the biomarkers listed in Table 4, and means for reporting said index value. - View Dependent Claims (17, 18, 19, 20, 21)
-
-
22. A medical diagnostic test system for evaluating risk for developing a diabetic condition, the system comprising:
-
a data collection tool adapted to collect biomarker measurement data representative of measurements of biomarkers in at least one biological sample from an individual; and an analysis tool comprising a statistical analysis engine adapted to generate a representation of a correlation between a risk for developing a diabetic condition and measurements of the biomarkers, wherein the representation of the correlation is adapted to be executed to generate a result; and an index computation tool adapted to analyze the result to determine the individual'"'"'s risk for developing a diabetic condition and represent the result as an index value; wherein said biomarkers comprise; (i) at least three biomarkers, where three of the biomarkers are selected from the RDMARKER sets listed in FIG. 6A ;
or(ii) at least four biomarkers selected from RDMARKERS;
or(iii) at least three biomarkers, where two biomarkers are selected from ADIPOQ;
CRP;
GLUCOSE;
GPT;
HBA1C;
HSPA1B;
IGFBP1;
IGFBP2;
INS;
LEP; and
TRIG; and
one biomarker is selected from the ALLDBRISKS, CPs, and TLRFs of Table 1, Table 2, and Table 3;
or(iv) at least three biomarkers, where at least one biomarker is selected from GLUCOSE and HBA1C;
at least one biomarker is selected from ADIPOQ, CRP, GPT, HSPA1B, IGFBP1, IGFBP2, INS, LEP, and TRIG; and
at least one biomarker is selected from the ALLDBRISKS, CPs, and TLRFs of Table 1, Table 2, and Table 3;
or(v) at least three biomarkers, where at least two biomarkers are selected from the biomarkers within the group consisting of Core Biomarkers I and Core Biomarkers II and at least a third biomarker is selected from any of the biomarkers listed in Table 4. - View Dependent Claims (23, 24)
-
-
25. A method of evaluating the current status of a diabetic condition in an individual, the method comprising:
-
obtaining biomarker measurement data, wherein the biomarker measurement data is representative of measurements of biomarkers in at least one biological sample from the individual; and evaluating the current status of a diabetic condition in the individual based on an output from a model, wherein the model is executed based on an input of the biomarker measurement data; wherein said biomarkers comprise; (i) at least three biomarkers, where three of the biomarkers are selected from the RDMARKER sets listed in FIG. 6A ;
or(ii) at least four biomarkers selected from RDMARKERS;
or(iii) at least three biomarkers, where two biomarkers are selected from ADIPOQ;
CRP;
GLUCOSE;
GPT;
HBA1C;
HSPA1B;
IGFBP1;
IGFBP2;
INS;
LEP; and
TRIG; and
one biomarker is selected from the ALLDBRISKS, CPs, and TLRFs of Table 1, Table 2, and Table 3;
or(iv) at least three biomarkers, where at least one biomarker is selected from GLUCOSE and HBA1C;
at least one biomarker is selected from ADIPOQ, CRP, GPT, HSPA1B, IGFBP1, IGFBP2, INS, LEP, and TRIG; and
at least one biomarker is selected from the ALLDBRISKS, CPs, and TLRFs of Table 1, Table 2, and Table 3;
or(v) at least three biomarkers, where at least two biomarkers are selected from the biomarkers within the group consisting of Core Biomarkers I and Core Biomarkers II and at least a third biomarker is selected from any of the biomarkers listed in Table 4. - View Dependent Claims (26, 27, 28, 29, 30)
-
Specification